信立泰(002294.SZ)擬轉讓鹽酸厄洛替尼、利伐沙班內地權益予藍谷藥業
格隆匯 12 月 28日丨信立泰(002294.SZ)公佈，為聚焦核心戰略領域、專注創新研發，提高資產運營效率，公司擬與青島藍谷藥業有限公司(“藍谷藥業”)簽訂協議，轉讓公司所有的鹽酸厄洛替尼、利伐沙班產品在中國大陸地區的權益。公司將根據協議進展情況，按里程碑獲得總金額為人民幣8400萬元的技術轉讓費。
此次交易標的，為公司擁有的鹽酸厄洛替尼(製劑及原料)、利伐沙班(製劑及原料)產品在中國大陸地區的權益，包括但不限於藥品批文、研發、生產、銷售、市場推廣等所有權益等。公司將根據協議進展情況，按里程碑獲得總金額為人民幣8,400萬元的技術轉讓費。
鹽酸厄洛替尼、利伐沙班為4類化學仿製藥。其中，鹽酸厄洛替尼開發適應症擬為：用於既往接受過至少一個化療方案失敗後的局部晚期或轉移的非小細胞肺癌(NSCLC)。利伐沙班開發適應症擬為：用於擇期髖關節或膝關節置換手術成年患者，以預防靜脈血栓形成(VTE)；用於治療成人深靜脈血栓形成(DVT)，降低急性DVT後DVT復發和肺栓塞(PE)的風險；用於具有一種或多種危險因素(例如：充血性心力衰竭、高血壓、年齡≥75歲、糖尿病、卒中或短暫性腦缺血發作病史)的非瓣膜性房顫成年患者，以降低卒中和全身性栓塞的風險。目前，公司已申報生產，預計2021年一季度獲得註冊批件。
隨着醫藥行業發展趨勢日益明朗、創新政策的深化落地，近年來，公司圍繞心腦血管、骨科、降血糖等核心領域，不斷集中資源，專注重點項目的創新研發，並終止了部分已進入臨牀階段的仿製藥項目。此次公司轉讓仿製藥鹽酸厄洛替尼、利伐沙班相關的權益，將進一步提高資產運營效率，並獲得相關轉讓收益，符合公司發展戰略及規劃。此次轉讓不涉及公司核心專利技術，不會對公司正常生產經營產生不利影響，不存在損害公司和中小股東合法權益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
